Antibodies against the ectodomain of ErbB3 and uses thereof

US8691225B2 · kind B2 · utility

Assignee

• Merrimack Pharmaceuticals, Inc. · US

Inventors

• Birgit Schoeberl · Cambridge, US
• Ulrik Nielsen · Quincy, US
• Michael Feldhaus · Lebanon, US
• Arumugam Muruganandam · Bengaluru, IN
• David Buckler · Mount Olive, US

Key dates

• Filing date: Aug 21, 2009
• Grant date: Apr 8, 2014
• Expiry date: Sep 8, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.